Only the second ever 'Outstanding Contributions to the Society' Award was made to George Galasso. George was a former President (1992) (1993) (1994) and has hugely supported the Society almost from its inception. Earl Kern (President 1996 -1998 is the only other winner of this award to date.
Special awards were also made at 20th ICAR to two strong supporters of, and contributors to, both ISAR and ICAR, Drs Kirk Field and Bob Sidwell. They each received plaques with the following inscription: 'In recognition and gratitude of many years of loyal service to the Society', a sentiment warmly echoed by the ICAR audience.
In addition to these richly deserved awards to our more senior brethren, we also held a very successful poster prize competition, brought together by Bob Buckheit and his committee. Six awards were made in three categories to Henning Jessen, Youcef Mehellou, Gemma Moncunill, Mireille St. Vincent, Koleen Herlihy and Ashoke Sharon. As with much of the 20th ICAR, details of their work are available on the website with thanks to Andrea Brancale, our webmaster. Members will notice more and more being added to the website; some of it will be for members only and password protected. Members in good standing in July will receive a new password for the next year. Please be sure to renew your membership now if it is expiring, to be able to access the members' area, and to beat the fee rise.
For the first time in 2007 we ran an electronic election to the Board. This was highly successful. We welcomed back Masanori Baba as a Board member and were pleased to welcome Johan Neyts and Phil Furman as new Board Members. Dale Barnard was also elected to take over from our dedicated outgoing treasurer, John Morrey. Support for the 20th ICAR, and ISAR in general, is provided by Courtesy Associates -about whom our feedback is always highly positive. In 2007 they helped us run our first electronic feedback on the meeting. This led to record levels of feedback. Of the comments to date (approximately 100 returns) not a single person was 'not satisfied' with this year's conference, and 72% of those that responded were 'very' or 'mostly' satisfied. The overall score for the meeting was 3.9/5, compared with 3.5 for the 19th ICAR, and most people felt that this year's meeting equalled (70%) or exceeded (20%) previous years. The top four items selected as particularly positive were: the hotel, the clinical symposium, the poster sessions and the 'quality' of information presented. Three quarters of those that responded felt the balance of plenaries was about right, whereas 23% felt that there were too few. We will try to introduce a couple more into the 21st ICAR, budgets allowing. A number of positive suggestions for improvement were made, for which we are very grateful. Our new Programme Committee Chair for the 21st ICAR, Bob Buckheit, will take full account of these in helping to plan our next meeting. We also received 14 offers of help on our committees -we will be in touch to take advantage of these kind offers.
The 2008 Scientific Program for the 21st ISAR is already starting to take shape in response to the survey. We believe the ICAR meeting is changing to provide higher quality science, a shorter duration meeting with more intensity to the science, and with new and novel symposia to provoke interest. The Program Committee Chair, Bob Buckheit, welcomes your suggestions for the continued enhancement of the annual meeting to fit your needs. We hope that all members of the Society will consider submitting their cutting edge science to the meeting as abstracts later this year in order to contribute to the scientific programme of the Montreal meeting.
As always I am delighted as President to hear from any member as to how we can improve our service yet more. Please e-mail me on ISAR@cardiff.ac.uk.
20th ICAR Highlights (Anthony Vere Hodge)

Introduction
This review of the 20th ICAR attempts to give an overview of the conference highlights. As this is a research conference, any references to clinical results should not be taken as a recommendation for clinical use. I wish to thank all those authors who have kindly provided me with copies of their presentations. This report would be much the poorer without their input.
A short report, focused on the highlights of the contributors' presentations, was published in July 2007 issue of Future Virology (R Anthony Vere Hodge (2007) Highlights of the 20th International Conference of Antiviral Reserch (ICAR). Future Virology 2:329-330) and it is incorporated into this review.
Satellite symposium 'Clinical updates on antiviral drugs'
Mick Hitchcock (Gilead, Foster City, CA, USA) described the progression of an HIV integrase inhibitor, elvitegravir An interaction study investigated the pharmacokinetics of ATC with tipranavir/ritonavir. There was a marginal increase in area under the curve (AUC; 1.4-fold) and plasma peak concentration (C max ; 1.25-fold), but did not warrant a dose adjustment. In a study investigating the potential for an effect on the heart (QTC study), ATC (1,600 mg) showed no significant effect. In a Phase IIb study, ATC (600 or 800 mg twice daily) was added to failing highly active antiretroviral therapy. At day 21, highly active antiretroviral therapy was optimized and at week 24, all patients were put on the higher dose of ATC. At day 21, the reduction in HIV viral load was 0.8 log 10 (both ATC groups combined). There was no emergence of resistance to ATC. This result compares favourably with other nucleoside reverse transcriptase inhibitors (NRTIs) in development.
Alice Robertson (Chimerix Inc., Durham, NC, USA) reported on the initial Phase I trial of 1-O-hexadecyloxypropyl-cidofovir (CMX001). As the gastrointestinal (GI) tract was the target organ in animal toxicology, GI tract monitoring with a wireless capsule endoscopy is a key feature of this trial. The subjects took a wireless capsule on day -1 to give a baseline and again on day 0 when CMX001 was given. The first two doses, 25 and 50 μg/kg, have been completed successfully.
Although this work is continuing, CMX001 seems to have been overtaken by ST-246, but combination with ST-246 may be possible (see below).
Stephen Villano (ViroPharma Inc, Exton, PA, USA) reported that ViroPharma acquired maribavir in 2003 from GSK for use in transplant patients. In a Phase II trial in stem cell-transplant (STC) patients, placebo was compared with maribavir over the 12-week high-risk period for cytomegalovirus (CMV). CMV surveillance was done weekly using CMV pp65 antigenaemia and CMV DNA by PCR. If CMV was detected, the patients were given open therapy, usually ganciclovir intravenously. Taste disturbance was the main side effect of maribavir. Although there was no clear dose response, maribavir did reduce the risk of CMV. A Phase III trial will have a similar design but with a 1-year follow-up.
Ronald Moss (Vical, San Diego, CA, USA) summarized progress with DNA vaccines. Three DNA vaccines are licensed for use in animals, but none in humans. Their potential advantages are that they are simple to administer (intramuscular, rather than intradermal, injection), their production does not involve growing dangerous viruses and they have had a good safety record. In one trial with a bivalent CMV vaccine (genes for pp65 and gB), about half the individuals were responders by conventional ex-vivo ELISPOT assay. However, when samples were re-examined with a cultured ELISPOT assay, which includes the central memory cells, about two-thirds of the individuals were responders. So it may be that the DNA vaccine is priming long-term memory cells. In this trial, the vaccine was formulated with CRL1005 poloxamer adjuvant. In animals, a cationic adjuvant is very effective. The choice of adjuvant may be crucial.
Elion and Prusoff Awards
Elion Award Lecture: Influenza Antivirals: Progress, Problems and Future Prospects by Frederick Hayden (University of Virginia, Charlottesville, VA, USA, seconded to Global Influenza Program, WHO, Geneva, Switzerland) . The publication of the crystal structure of influenza virus neuraminidase in 1993 opened the door to a new era in anti-influenza agents. Zanamivir (1993) was the first potent, selective neuraminidase inhibitor (NI). Oseltamivir (1997) was the first oral NI. These NIs entered clinical practice in 1999. The problem of resistance with amantadine and rimantadine is well known, with resistant virus emerging quickly and being fully viable. Widespread resistance led the Centers of Disease Control and Prevention to recommend US clinicians not to use these inhibitors. Fortunately, resistance to oseltamivir is infrequent, especially with N2 viruses. With N1 viruses, a H274Y mutation makes it >400-fold resistant to oseltamivir. So far, only low-level transmission of resistant virus has been detected, possibly because the virus is disabled.
Elion awardee Frederick Hayden
With N1 viruses, the H274Y and N294S mutants are highly resistant to oseltamivir, but remain susceptible to zanamivir; intravenous (IV) studies have been considered. Peramivir is another NI being evaluated by an IV route. T-705, an inhibitor of influenza RNA polymerase, has showed excellent activity in an influenza (H5N1)-mouse model, is active orally and is starting clinical evaluation. A South-East Asia Influenza Clinical Research Network has been established to aid the initiation of clinical studies with new compounds and, in future, to test combinations of agents.
Prusoff Award Lecture: Prodrugs of antiviral nucleotides and phosphonates -the cycloSal story by
Chris Meier (University of Hamburg, Germany). There had been various chemical approaches used to make nucleotide analogues more lipophilic to aid their entry into cells. With the cycloSal approach, the two hydroxyl groups are linked via a cyclic structure. The substituent on the cycloSal moiety influences chemical stability. Whereas stavudine (d4T) is essentially inactive against HIV-2 in TK-deficient CEM cells (CEM TK-def ), 3-Me-cycloSal-d4T retains full activity (EC 50 =0.1 μM). Another example, cycloSal acyclovirmonophosphate (ACVMP) was active against a TK-def strain of HSV-1 and had comparable activity to cidofovir against vaccinia virus.
Stereochemistry about the phosphate is important. The antiviral activities against HIV-2 in CEM TK-def cells differed (EC 50 =0.08 μM and 0.42 μM, respectively) for the R p and S p diastereomers. Also, some inhibition of human serum cholinesterase (BChE) was observed (IC 50 s>50 μM and 0.24 μM, respectively). Using radiolabelled compounds, levels of d4T triphosphate in CEM TK-def cells were much enhanced with the cycloSal compound.
The most recent development of the cycloSal story is to synthesize 5-acylal-or 5-aminoacyl-cycloSal-esters. The idea is that these compounds would be relatively stable chemically but within a cell would be subject to enzymatic action, which would then ensure intracellular trapping and allow rapid chemical hydrolysis to release the antiviral agent.
HCV mini-symposium
Translational control in HCV infection. One general cellular antiviral strategy is to detect the presence of doublestranded RNA (dsRNA) which activates the dsRNAdependent protein kinase (PKR), which, in turn, shuts down all host translation. Joseph Puglisi (Stanford University, Stanford, CA, USA) described how HCV avoids this mechanism. The dsRNA brings two molecules of PKR close together so that intermolecular phosphorylation (activation) becomes possible. Host translation involves an internal ribosome entry site (IRES) and a cap protein which scans the mRNA for the start codon, AUG. HCV also has an IRES but a cap protein is not needed. HCV IRES is a potent activator of PKR, which leads to a shut-down of capdependent translation but HCV translation continues. Is it possible to direct an antiviral at the HCV IRES?
Do any HCV-infected patients ever clear the virus?
Thomas Michalak (Memorial University of Newfoundland, St John's, Canada) noted that ~15% of patients recover spontaneously. However, his research assay can detect <10 genome copies/ml and the (-)RNA (replicative) strand. HCV, including (-)RNA, was found in stimulated peripheral blood mononucelar cells. So far, every patient had HCV. These include patients who had recovered spontaneously and those who responded to interferon (IFN) therapy. Replication of HCV in T cells in culture has been successful. The tentative conclusion is that all patients with HCV infection continue to have replicating HCV, albeit at a very low level. So HCV disease could re-emerge in any patient.
Telaprevir TVR) . Ann Kwong (Vertex Pharmaceuticals, Cambridge, MA, USA) reported that TVR, a protease inhibitor (PI), is in Phase II trials. Other HCV PIs include BILN2061 (Boelringer Ingelheim, discontinued), ITMN191 (Roche) and SCH503034 (Schering-Plough). Judged by IC 50 values, BILN2061 is more potent than TVR, (1 nM versus 350 nM respectively); however, if the IC 99.9 values are compared (2 μM versus 6 μM, respectively), the compounds are similar. In a mouse liver model, the two compounds are, again, similar. In a Phase Ib trial, the best dose (750 mg three times daily) gave ~2 log 10 reduction in HCV RNA in 2 days. To investigate resistance mutations, colonies were cloned from each patient and sequenced. Compared to wild type, the mutations were T54A (sixfold resistant), V36A/M (7), R155K/T (7/20) and A156V/T (>74). There was a negative correlation between resistance and viral fitness. All the TVR-resistant strains were fully sensitive to IFN. The next Phase II trial tested TVR with Valopicitabine (NM283, being developed by Idenix/Novartis) is the valine oral produg of NM107. In a Phase IIa trial with HCV, NM283 (800 mg once daily) was much more effective when combined with IFN than as monotherapy (HCV RNA reduced by 4.5 and 0.9 log 10 , respectively). In a Phase IIb trial, two doses of NM283 (800 and 200 mg once daily, both with pegylated IFN) were compared for 48 weeks. Due to GI side effects, there was a dose reduction at about 20 weeks with the 800 mg dose. At 48 weeks with the 200 mg dose, 53% of the patients were below quantification level (=20 IU/ml). However, no patient had a sustained response.
R1626, the tri-isobutyrate prodrug of R1479 (Roche), in a monotherapy Phase I study reduced the mean viral load by 3.7 log 10 at 14 days with the highest dose (4,500 mg twice daily). In a Phase II trial, R1626 (1,500 and 3,000 mg doses) will be tried with IFN.
HCV-796 (ViroPharma/Wyeth) and HCV-371 (ViroPharma) bind to the palm and thumb regions, respectively. In a phase II trial with HCV-796, monotherapy was compared with same doses (up to 1,000 mg twice daily) combined with pegylated IFN for 14 days. In one patient, there was a serious adverse event, a seizure, on day 1. After a halt for review, other patients were treated without a problem. On monotherapy, there was a reduction in viral load by day 4, but this rebounded while still on therapy. The combination gave up to a 3.3 log 10 reduction during the 14-day therapy.
Maybe, like the non-NRTIs for HIV, this class of compounds must be used only in combination with NRTIs?
Discovery of dihydopyrones as potent inhibitors of HCV polymerase. John Tatlock (Pfizer, San Diego, CA, USA) summarized their work starting with a lead compound with modest activity (IC 50 =0.9 μM). This compound binds to the thumb region of the polymerase. Structure-activity relationship (SAR) studies led to two compounds with better activity (IC 50 =30-40 nM), better metabolic stabilities and good oral bioavailabilities.
Hepatitis C. The current epidemic. Tarek Hassanein (University of California, San Diego, CA, USA) concluded the mini-symposium on HCV with a clinical overview. The prevalences, from <1% to >10%, and the six genotypes vary across countries. In the USA, the incidence of HCV in children is very low. Currently, about 70% of new infections are in IV drug users. As HCV disease progresses over a long period, it is estimated that the demand for treatment will peak at about the year 2020 from those infected before blood donation screening began in 1990.
Interesting new compounds
GS-8374, a novel phosphonate HIV PI. Tomas Cihlar (Gilead, Foster City, CA, USA) described the evaluation of GS-8374. It inhibited HIV protease (K i =8 pM), was active against HIV in cell culture assays (EC 50 about 5 nM), but was not cytotoxic (CC 50 >40 μM). GS-8374 retained good activity (mean EC 50 =7 nM) against a panel of resistant HIV. This resistance profile was superior to various PIs including darunavir. Molecular modelling suggested that the solvent-exposed phosphonate group allows GS-8374 to explore multiple binding modes of the active site.
RO-0622, a novel nucleoside analogue with potent activity against HCV. Klaus Klumpp (Roche Palo Alto LLC, CA, USA) reported that RO-0622 (2′-α-deoxy-2′β-fluoro-4′-azido-cytidine) was a potent inhibitor of HCV (EC 50 =24 nM in replicon assay), was efficiently phosphorylated in primary human hepatocytes and showed good pharmacokinetics in animals. No toxicity was seen up to a dose level of 2,000 mg/kg daily in a 2-week study.
GS-327073, a non-nucleoside inhibitor of HCV
polymerase. Of a series of imidazopyridines, GS-327073 was one of the most potent (EC 50 =4 nM in replicon assay, CC 50 >16 μM). The investigation of its mode of action was reported by Inge Vliegen (Rega Institute, Leuven, Belgium). Highly resistant virus (EC 50 >11 μM) was obtained, but only after 6 months in replicon system. Resistant mutations were shown to be in the HCV polymerase gene at or very close to the catalytic site, offering an explanation for the slow emergence of resistance.
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Drs Richard Whitley and Joe Patti enjoy the reception 5-Azacytosine. There were four presentations on new compounds with the 5-azacytosine moiety. Marcela Kremerova (Gilead and IOCB Research Center, Prague, Czech Republic) described the initial evaluation in cell culture assays. Graciela Andrei (Rega Institute) reported that the anti-herpes (HSV-1) and anti-pox virus (Vaccinia) activities of HPMP-5-azaC and cHPMP-5-azaC were comparable to HPMPC (cidofovir) and cHPMPC in standard cell culture assays, organotypic epithelial raft cultures and mouse models. The HDE-cHPMP-5-azaC was more potent than the parent compound in the cell culture assays, the raft cultures and gave good activity in the mouse/HSV model, but was less active than the parent compound in the mouse/vaccinia model, possibly due to poor distribution of the ester to the lungs. Sophie Duraffour (Rega Institute) reported that the aza-C compounds were active against camelpox virus in cell culture and raft cultures. Lieve Naesens (Rega Institute) examined the intracellular metabolism of HPMP-5-azaC. The diphosphate (the active moiety) had a half-life of 43 h. Furthermore, this compound was incorporated into cellular DNA, markedly more than with cidofovir. Although the aza analogue of cidofovir seems to have many good antiviral activities, should the incorporation into cellular DNA be taken as a toxicology warning sign?
ST-246 active against Pox viruses. Robert Jordan (SIGA Technologies, Corvallis, OR, USA) summarized the final efficacy studies, with variola virus and monkey pox virus in cynomolgus monkeys. In a placebo group, variola (10 8 PFU IV) led to severe infection with >1,250 pox lesions and 33% mortality. Oral treatment with ST-246, starting 24 h post infection (pi), resulted in a dramatic improvement with no pox lesions. A similar result was obtained in the monkey pox test. The placebo controls had >1,500 pox lesions and 100% mortality. With ST-246 therapy starting at 24 h pi, there were no pox lesions. With treatment starting 72 h pi, there were no lesions in 2/3 animals and <5% of the control lesions in the third animal. An investigative new drug (IND) application for ST-246 has been approved with fast-track status.
The potential for synergy between ST-246 and CMX001 was reported by Debra Quenelle (University of Alabama, Birmingham, AL, USA) using cowpox virus in a mouse model. With treatment starting 6 days pi, neither ST-246 nor CMX001 prevented death but the combination at the higher doses gave 93% survival. There seemed to be a synergistic effect between these two compounds, especially with delayed dosing.
Other new compounds. A series of 7-deazaneplanocin A analogues were synthesized and evaluated as anti-hepatitis B virus (HBV) agents. Hyo-Joong Kim (University of Georgia, GA, USA) reported that the 7-ethynyl compound had good activity (EC 50 =0.3 μM, CC 50 >300 μM). There was little change in activity against a panel of lamivudineresistant HBV and approximately twofold loss with adefovir-resistant HBV.
Steven Carroll (Merck Research Laboratories, West Point, PA, USA) reported that 7-deaza-7-fluoro-2′-C-methyladenosine was active in a HCV replicon assay, but the main interest was the pharmacokinetics. In rats and dogs, the halflife (t 1/2 ) in the liver was about a day and drug levels remained above the EC 90 concentration for nearly 7 days.
Bo Oberg (Medivir AB, Huddinge, Sweden) described how PPI-801 (2′,3′-dideoxy-3′C-hydoxy-methyl cytidine) retains activity against HIV RTs, with thymidine analogue or nucleoside analogue mutations (TAMs or NAMs). These are generally highly effective in removing the incorporated nucleoside analogue from the HIV DNA chain but not PPI-801. In a SIV-infected monkey, systemic infection was prevented by PPI-801 (3×10 mg/kg daily for 3 days starting from 1 to 3 h pi). Interestingly, 1-day treatment was not sufficient to prevent systemic infection. An oral prodrug, PPI-802, is being developed.
New concepts -new targets
HIV maturation. Within the immature HIV virion, Gag protein is processed by HIV protease to form mature, infectious virions. PIs inhibit this maturation. Chris Aitken (Vanderbilt University, Nashville, TN, USA) described the mode of action of 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (DSB). DSB binds to the immature form of Gag and so prevents cleavage at the CA-p2 site. A variety of substitutions at the CA-p2 junction can markedly increase HIV resistant to DSB. Although DSB itself would not be a useful anti-HIV agent, this work has identified a new target for antivirals. So a scintillation proximity-based assay, using radiolabelled DSB, has been set up to screen for compounds that bind to the immature Gag protein. Institute) proposed the use of carbohydrate-binding agents, such as Pradimicin A (PRM-A) for HIV therapy and possibly other enveloped viruses. In cell culture, resistance can occur, albeit slowly, but the mutant strains loose glycosylation sites. However, in HIV-infected patients, loss of a glycosylation site exposes some of the HIV gp120 protein surface to the immune system. Thus, the more resistant the HIV becomes towards PRM-A, the more immunogenic it may become. At this meeting, Jan Balzarini reported that there was a close correlation in the respective activities of carbohydratebinding agents against HIV and HCV. However, his concept got further support in another presentation about resistance to enfuvirtide (T-20), by Stefano Aquaro (University of Calabria, Rende, Italy). Addition of T-20 to previous therapy gave a benefit through 48 weeks in terms of CD4 + T-cell counts, but only for 8 weeks in terms of HIV viral load. Some mutations associated with resistance were also associated with a decrease in CD4 + T-cell counts, but the mutation N126K, in particular, removes a glycosylation site and was associated with a gain in CD4 + T-cell counts. This appears to be the first example in which resistance to a drug leads to the loss of a glycosylation site, which, in turn, leads to a stronger immune response against HIV.
Mark Prichard (University of Alabama) proposed a new approach to antiviral therapy arising from work investigating the mechanism of action of maribavir. Nuclear aggresomes are cellular structures which sequester aggregated proteins, such as viral proteins. They arise from promyelocytic (PML)associated aggregates and their formation is stimulated by retinoblastoma (RB) protein. CMV UL97 kinase inactivates RB and so inhibits the removal of viral proteins by the aggresome process. Maribavir inhibits UL97 kinase activity and thereby prevents the inactivation of RB. As RB is a tumour suppressor, which plays a key role in cell cycle control, proliferative disorders associated with CMV infection may respond to maribavir or other kinase inhibitors.
Vaccinia virus thymidine kinase (VV TK). The orthopoxvirus TKs are highly homologous to cellular TK1. However, previous work had indicated that some nucleoside analogues were phosphorylated preferentially by the poxvirus TK. Earl Kern (University of Alabama) reported the crystal structure of VV TK. Although the active site of VV TK is, indeed, similar to the human TK, the virus TK can accommodate larger nucleoside analogues by the active site opening slightly.
Emma Harden (University of Alabama at Birmingham, Birmingham, AL, USA) reported on the selective activation of deoxyuridine substituted with six groups of differing size. All six compounds were at least 20-fold less active against TK-negative strain of cowpox virus. Kinetic studies with purified VV TK and human TK1 confirmed that all six analogues were good substrates for the viral TK, not human TK.
Antiviral properties of compounds in clinical use.
There were several presentations investigating the antiviral properties of compounds already licensed for clinical use. Nitazoxanide, for Cryptosporidium parvum enteritis, is in clinical trials for HBV and HCV. Debio-025, a non-immunosuppressive analogue of cyclosporin A (CsA), is in Phase II trials for HCV. Gefitinib, a cancer therapy, is known to inhibit human CMV UL97 kinase activity. Considering Mark Prichard's suggestion (see above), could gefitinib control CMV-induced proliferative disorders? Trioxsalen, used with UV light to treat vitiligo, is a potent inhibitor of the NS3 helicase activity, a new class of anti-HCV agent.
Conclusion
It is impossible to record all the interesting presentations in this review, but it is hoped that sufficient information has been included to demonstrate that the 20th ICAR had much of value. I would like to add my thanks to the ISAR Officers and Conference Committee for organizing another successful ICAR meeting, a good start to the third decade of the society.
Business meeting (Joe Colacino)
The 
